Osimertinib, a revolutionary drug in treating EGFR-mutant non-small cell lung cancer (NSCLC), is making waves in oncology. Osimertinib, also known as Tagrisso. Developed initially as a second-line treatment for patients with resistant forms of lung cancer, Osimertinib has gained importance as a first-line therapy in recent years. With its ability to...